“…18 Focusing on positive tests, the expected pros of CZT are a more correct classification of ischemic patients in terms of ischemia severity (e.g., in keeping with the Maximal Ischemia Score [MIS], distinguishing minimal, mild, moderate or severe ischemia), extension, and involvement of the corresponding coronary vessel, in particular, the left anterior descending (e.g., single-vessel-related ischemia [VRI] versus multiple VRI, with or without left anterior descending involvement). 4,5 Accordingly, we may more accurately proceed with risk stratification and choice of subsequent clinical management. Focusing on the evaluation of end-diastolic perfusion, another advantage of CZT is the possibility of significantly reducing false-positive results in patients with left bundle branch block (Figure 1), who typically display a perfusion abnormality which is more severe in the endsystolic phase than in the end-diastolic phase, at odds with ischemic patients (Figure 2).…”